Table 3.
Detailed characteristics of the included trials.
| Number | Percent | |
|---|---|---|
| Locations | ||
| Single continent | 41 | 91.1 |
| Asia | 6 | 14.6 |
| Europe | 12 | 29.3 |
| North America | 17 | 41.5 |
| South America | 2 | 4.9 |
| Africa | 3 | 7.3 |
| Oceania | 1 | 2.4 |
| Multiple continents | 4 | 8.9 |
| 2 continents | 3 | 75.0 |
| >2 continents | 1 | 25.0 |
| Study sponsor | ||
| University | 11 | 24.5 |
| Hospital | 6 | 13.3 |
| Industry | 18 | 40.0 |
| Other | 10 | 22.2 |
| Collaborators | ||
| NP | 32 | 71.1 |
| Has collaborators | 13 | 28.9 |
| Funder type | ||
| Other | 29 | 64.5 |
| Other/industry | 4 | 8.9 |
| Industry | 11 | 24.4 |
| Industry/U.S. Fed | 1 | 2.2 |
| Data monitoring committee | ||
| Has data monitoring committee | 22 | 48.9 |
| Not have data monitoring committee | 15 | 33.3 |
| NP | 8 | 17.8 |
| Study results | ||
| Has results | 6 | 13.3 |
| No results | 39 | 86.7 |
| Publications of the study | ||
| No publications | 34 | 75.6 |
| Has publications | 11 | 24.4 |
| <2 publications | 3 | 27.3 |
| ≥2 publications | 8 | 72.7 |
| IF of publications | ||
| 0 < IF < 5 | 3 | 27.3 |
| 5 ≤ IF < 10 | 2 | 18.2 |
| 10 ≤ IF < 40 | 0 | 0.0 |
| IF ≥ 40 | 6 | 54.5 |
NP, not provided.